159 related articles for article (PubMed ID: 32564116)
1. ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.
da Costa Junior LC; de Castro CL; Freitas-Alves DR; Vianna-Jorge R; Santos PCJL
Eur J Clin Pharmacol; 2020 Oct; 76(10):1401-1408. PubMed ID: 32564116
[TBL] [Abstract][Full Text] [Related]
2. Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.
de Castro CL; da Costa Junior LC; Lourenço LV; Seba KS; da Silva TSL; Vianna-Jorge R
Arch Gynecol Obstet; 2019 Aug; 300(2):395-407. PubMed ID: 31123858
[TBL] [Abstract][Full Text] [Related]
3. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Ferracini AC; Lopes-Aguiar L; Lourenço GJ; Yoshida A; Lima CSP; Sarian LO; Derchain S; Kroetz DL; Mazzola PG
Clin Transl Sci; 2021 Mar; 14(2):720-728. PubMed ID: 33326171
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
[TBL] [Abstract][Full Text] [Related]
5. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P; Singh N; Sharma S
J Biochem Mol Toxicol; 2023 Mar; 37(3):e23269. PubMed ID: 36507589
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Krivak TC; Darcy KM; Tian C; Bookman M; Gallion H; Ambrosone CB; Deloia JA
Gynecol Oncol; 2011 Jul; 122(1):121-6. PubMed ID: 21496891
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.
Jiko M; Yano I; Sato E; Takahashi K; Motohashi H; Masuda S; Okuda M; Ito N; Nakamura E; Segawa T; Kamoto T; Ogawa O; Inui K
Int J Clin Oncol; 2007 Aug; 12(4):284-90. PubMed ID: 17701008
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
9. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
[TBL] [Abstract][Full Text] [Related]
11. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
Björn N; Jakobsen Falk I; Vergote I; Gréen H
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):277-287. PubMed ID: 29504705
[TBL] [Abstract][Full Text] [Related]
13. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Johnatty SE; Beesley J; Paul J; Fereday S; Spurdle AB; Webb PM; Byth K; Marsh S; McLeod H; ; Harnett PR; Brown R; DeFazio A; Chenevix-Trench G
Clin Cancer Res; 2008 Sep; 14(17):5594-601. PubMed ID: 18765553
[TBL] [Abstract][Full Text] [Related]
15. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza MR; Skougaard K; Wihl J; Keldsen N; Damkier P; Peterson C; Vach W; Brøsen K
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):199-204. PubMed ID: 21955855
[TBL] [Abstract][Full Text] [Related]
16. Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients.
Liu HE; Bai KJ; Hsieh YC; Yu MC; Lee CN; Chang JH; Hsu HL; Lu PC; Chen HY
Biomed Res Int; 2014; 2014():937429. PubMed ID: 25250341
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
18. Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by
Narumiya K; Bollschweiler E; Hölscher AH; Yamamoto M; Drebber U; Alakus H; Metzger R; Warnecke-Eberz U
Future Oncol; 2020 Sep; 16(27):2075-2087. PubMed ID: 32611208
[No Abstract] [Full Text] [Related]
19. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Markman J; Zanotti K; Webster K; Belinson J; Peterson G; Kulp B; Markman M
Gynecol Oncol; 2004 Feb; 92(2):592-5. PubMed ID: 14766252
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]